Adults over 65 represent the fastest-growing demographic of cannabis patients, yet they face unique physiological considerations and systemic barriers that conventional approaches often overlook. Age-related changes in metabolism, polypharmacy interactions, and institutional biases create a perfect storm that demands specialized clinical attention.

Aging fundamentally alters cannabinoid pharmacokinetics through reduced hepatic metabolism, altered body composition, and decreased renal clearance, requiring dose adjustments that standard protocols don’t address. The endocannabinoid system itself shows age-related changes, with CB1 receptor density declining in certain brain regions while inflammatory pathways become hyperactive. Older adults typically present with complex polypharmacy scenarios where cannabinoids may interact with warfarin, benzodiazepines, or cardiac medications through CYP450 pathways. Evidence suggests particular promise for cannabinoids in age-related conditions like chronic pain, sleep disorders, and appetite stimulation, but the therapeutic window narrows significantly with age. Most concerning is the systematic exclusion of older adults from cannabis research, creating an evidence gap precisely where clinical need is highest. Current dispensary models and dosing guidelines fail to account for age-specific vulnerabilities like orthostatic hypotension risk or cognitive sensitivity.

“I’ve seen too many older patients benefit from thoughtful cannabinoid therapy to accept that ‘seniors and cannabis don’t mix.’ The key is recognizing that geriatric cannabinoid medicine isn’t just adult medicine with lower doses—it’s a distinct clinical discipline requiring specialized expertise.”

? Join the Conversation

Have a question about how this applies to your situation? Ask Dr. Caplan →

Want to discuss this topic with other patients and caregivers? Join the forum discussion →

Have thoughts on this? Share it: